Halozyme Sees Minimal Medicare Price Negotiation Impact Through 2035

Event summary

  • Halozyme projects zero to minimal impact on royalty revenue through at least 2035 based on the newly released draft Medicare Drug Price Negotiation Program proposed rule for IPAY 2029.
  • The outlook is supported by orphan drug protections and biosimilar entry impacts outlined in the proposed rule.
  • Halozyme's ENHANZE® drug delivery technology remains a key differentiator for partnerships, with no projected impact on new agreements.
  • The company will continue engaging with CMS and stakeholders to support policies recognizing innovation and preserving patient access.

The big picture

Halozyme's positive outlook on royalty revenue stability reflects the strategic importance of orphan drug protections and the resilience of its ENHANZE® technology in the face of Medicare price negotiations. The company's ability to maintain partnerships and innovate in drug delivery technologies positions it favorably within the biopharmaceutical sector, despite regulatory uncertainties. The broader industry trend of cost containment through Medicare negotiations underscores the need for biotech firms to adapt and advocate for policies that balance affordability with innovation.

What we're watching

Regulatory Clarity
How the final rule from CMS will align with Halozyme's projections and whether orphan drug protections remain intact.
Partnership Dynamics
The pace at which Halozyme can secure new ENHANZE® partnership agreements amid evolving Medicare policies.
Biosimilar Impact
Whether the entry of biosimilars will affect Halozyme's eligibility for Medicare price negotiations and revenue streams.